top of page

Changing the treatment landscape for multiple myeloma patients.

Our Clinical Trial

is now open!

Our Work

K36’s lead candidate is KTX-1001, a first-in-class, selective inhibitor of the histone methyltransferase (HMT) MMSET, which is overexpressed in up to 20% of multiple myeloma patients due to the t(4;14) translocation.

We developed KTX-1001 to provide a targeted therapy that specifically addresses the underlying cause of cancer for these multiple myeloma patients. KTX-1001 is the first therapeutic agent to enter the clinic that directly targets overexpression of MMSET.

Screen Shot 2023-04-27 at 2.33.12 PM.png

Our Mission

Creating breakthrough therapies for the unmet medical needs of cancer patients worldwide.

Our Vision

Translating epigenetic modulation of oncogenic pathways into first-in-class small molecule therapeutics.

bottom of page